The U.S.-listed shares of Danish drugmaker Novo Nordisk rose Tuesday following a report that an activist investor is building ...

By Rebecca Robbins Novo Nordisk will replace its chief executive, Lars Fruergaard Jorgensen, the company announced Friday, citing a sharp decline in its stock price that stemmed from increased ...

Year-to-date, Novo’s shares have dropped 25%, while Eli’s stock has gained 4.6%. The recent US weekly prescription data showed signs that Novo Nordisk ... prompting an 8% decline in its ...

Novo Nordisk (NVO) shares hit their highest level in over two months following a Financial Times report that activist hedge ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 currently. Several factors have contributed to this downward trend.

Novo Nordisk jumps 5% as Parvus Asset Management builds a stake to sway CEO succession amid leadership shakeup and pipeline ...

Novo Nordisk (NVO) stock plunges 44% YoY ... while the 200-day SMA of $111.72 highlights just how deep this decline has been. Adding insult to injury, the MACD (moving average convergence ...

March marked the stock’s worst monthly performance since July 2002 with a 27% decline. Andersen says that the biggest initial hit was from disappointing phase 3 data for Novo Nordisk’s most ...

Novo Nordisk CEO Lars Fruergaard ... loss drug space pressured the company's stock. "Considering the recent market challenges, the share price decline, and the wish from the Novo Nordisk ...

Year-to-date, Novo’s shares have dropped 25%, while Eli’s stock has gained 4.6%. The recent US weekly prescription data showed signs that Novo Nordisk may be losing ... prompting an 8% decline in its ...